Preliminary studies in the development of triamcionolone acetonide lipid nanocapsules

FORMICA ML,; ULLIO GAMBOA G; BENOIT J.P,; ALLEMANDI D,; PALMA S. D

Córdoba

Congreso; Tercera Reunión Internacional de Ciencias Farmacéuticas - RICIFA 2014; 2014

Facultad de Ciencias Quimicas - UNC

Triamcinolone acetonide (TAA) is a synthetic corticosteroid used to treat a broad spectrum of retinal diseases. The development of TAA dosage forms is limited due toits poor solubility in water and/or physiologically acceptable solvents1. The purpose of this work was to develop and characterizea novel lipid nanocapsule (LNC) formulation as drug delivery system for TAA. LNCs were prepared using an optimized phase inversion-based method2. Due to the poor solubility of TAA in the oily phase of the original formulation, two co-surfactants (captex® 500p -Glyceryl triacetate- and oleic acid) in three proportions: 20, 30 and 50% were tested. The average particle size, polydispersity index (PI) and zeta potential were measured. Acceptable results were obtained only with a 20% of both co-surfactants. LNCs with captex® 500p leads to about (42.3±0.2) nm size nanoparticles with a narrow size distribution (PI˂0.2) and a negative z potential(-4±1) mVwhile LNCswith oleic acid showed an average particle size of (37.0±0.5) nm and a PI below 0.1with a negative z potential (-11 ±5)mV. The obtained formulations allow the encapsulation of TAA and it could be a potential strategy to treat several ocular diseases of the posterior segment by intravitreal route. Further studies will be carried out to test the encapsulation efficiency and the long-term stability of these formulations.